Searched for
OUTLICENSING DEAL
Venus Remedies shares up as unit enters into pact with MylanIn terms of volume, 3.14 lakh shares of the company changed hands at the BSE, while over 11 lakh shares were traded at the NSE during the d...08 Sep, 2014, 05.16 PM IST- Anti-diabetes Molecules: Connexios inks licence deal with German pharma major Boehringer IngelheimFor Connexios, this sale of its anti-diabetes molecules to Boehringer Ingelheim is the first out-licensing deal by an Indian life-sciences ...07 May, 2014, 04.06 AM IST
- Connexios, India’s first drug-discovery product startup signs first out-licensing deal; marks a milestoneConnexios, India’s first drug-discovery product startup, has signed its 1st out-licensing deal, marking a milestone for the Indian pharma i...06 May, 2014, 05.22 PM IST
- Ranbaxy Deal – A positive trigger for Alembic Pharma's stockThere are 5 buy recommendations for the company's stock with a target price of Rs 99. The company's stock has hit the target price on Frida...09 Mar, 2013, 04.39 PM IST
- Glenmark Pharma set to reap R&D gains despite hiccupsThe research effort combined with good performance in its generics business has made investors lap up its stock in recent quarters.25 Dec, 2012, 01.53 PM IST
- Glenmark receives $25 mn from Sanofi as upfront paymentFollowing that clearance, the deal has now become effective and Glenmark has also received the first upfront payment of USD 25 million, it ...28 Jun, 2011, 04.26 AM IST
- Failures and doubting investors have not dissuaded Glenmark Pharma's Glenn SaldanhaGlenmark has netted over $200 million in milestone and upfront payments while it has spent about $120-130 million on research.22 May, 2011, 02.06 AM IST
- Glenmark Pharma: Molecule pipeline strong, but risks also highGlenmark is one of the few pharma companies to have successfully monetised the fruits of its innovative R&D.17 May, 2011, 02.30 AM IST
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...27 Sep, 2010, 12.24 PM IST
- Glenmark inks $325-mn licensing deal with SanofiGlenmark Pharmaceuticals licensed its chronic pain molecule to Sanofi Aventis for an upfront payment of $20 million (approximately Rs 89 cr...04 May, 2010, 02.47 AM IST
- Glenmark Pharma: Sanofi deal calms nerves, but co has a long way to goAfter a series of setbacks at monetising its research, the company has finally cracked an out-licensing deal with global major Sanofi-Avent...04 May, 2010, 12.16 AM IST
- Medicis deal, generic biz to boost financialsRecent developments could well be a pointer to better days ahead for Glenmark Pharma which has had a relatively poor performance in the pas...17 Nov, 2009, 01.08 AM IST
- Suven Life Sciences in demand on Alzheimer drug dealShares of Suven Life Sciences touched a 52-week high after the firm said it was in talks with four global pharmaceutical firms, which have ...25 Aug, 2009, 11.06 AM IST
- Outlicensing deals a leg up for drug researchRecent drug outlicensing deals by Indian pharma companies have created much hope for research initiatives in the country.10 Aug, 2007, 12.55 AM IST
- Ranbaxy closes second out-licensing dealRanbaxy Laboratories’ research programme moved up by a step. Its novel statin is the second compound from the company’s new drug discovery ...02 Mar, 2007, 12.54 AM IST
- Milestone for GlenmarkGlenmark’s out-licensing deal with the German pharma major, Merck KGaA, for its diabetes molecule, a DPP-IV inhibitor, is an important mile...19 Oct, 2006, 12.52 AM IST
- Ethypharm signs out-licensing deal with GlobalpharmaPharma major Ethypharm India, has signed a major out-licensing deal for five new products in different therapeutic segments, with UAE-based...10 Aug, 2006, 07.20 PM IST
Load More
